(68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study

(68)Ga-labeled fibroblast activation protein inhibitor ((68)Ga-FAPI) PET/CT has demonstrated promising clinical results, with a higher SUV(max) and tumor-to-background ratio (TBR) in breast cancer (BC) patients than (18)F-FDG PET/CT. Here, we aimed to evaluate the suitability of (68)Ga-FAPI PET/CT f...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ling, Zheng, Shan, Chen, Linying, Xu, Sunwang, Wu, Kunlin, Kong, Lingjun, Xue, Jiajie, Chen, Xiangjin, Miao, Weibing, Zhu, Youzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690122/
https://www.ncbi.nlm.nih.gov/pubmed/37918866
http://dx.doi.org/10.2967/jnumed.123.266079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690122/
https://www.ncbi.nlm.nih.gov/pubmed/37918866
http://dx.doi.org/10.2967/jnumed.123.266079

Ejemplares similares